34
With apologies to Charles Dickens, the market for gene therapies can be summed up as being in “the best and worst of times.”
On the best side, five gene therapy developers have raised a combined $534.4 million in venture capital (VC) financing this year (as of April 14). Tune Therapeutics, a developer of epigenome editing therapies, garnered over $175 million in Series B funding in January, while Atsena Therapeutics earlier this…